Adrenocortical adenoma and carcinoma: Histopathological and molecular comparative analysis

Modern Pathology

Volumn 16, Issue 8, 2003, Pages 742-751

  Stojadinovic, Alexander ^b   Brennan, Murray F ^a   Hoos, Axel ^a   Omeroglu, Atilla ^a   Leung, Denis H Y ^c   Dudas, Maria E ^a   Nissan, Aviram ^a   Cordon Cardo, Carlos ^a   Ghossein, Ronald A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c SINGAPORE MANAGEMENT UNIVERSITY   (Singapore)

Author keywords

Adenoma; Adrenal; Carcinoma; IHC; Tissue microarray

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR MARKER;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHODOLOGY; MITOSIS; MITOSIS RATE; MOLECULAR GENETICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR CELL; TUMOR NECROSIS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041387353     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000081730.72305.81     Document Type: Article

References (32)

1. Reincke M, Beuschlein F, Slawik M, Borm K. Molecular adrenocortical tumorigenesis. Eur J Clin Invest 2000;30:63-8.
2. Mantero F, Arnaldi G. Management approaches to adrenal incidentalomas: a view from Ancona, Italy. Endocrinol Metab Clin North Am 2000;29:107-25.
3. Barnett CC, Varma DG, El-Naggar AK, Dackiw AP, Porter GA, Pearson AS, et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 2000;128:973-83.
4. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.
5. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6.
6. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Brennan MF, Jaques DP. Adrenocortical carcinoma: clinical, morphologic and molecular characterization. J Clin Oncol 2002;20:941-50.
7. Grondal S, Cedermark B, Eriksson B, Grimellus L, Harach R, Kristoffersson A. Adrenocortical carcinoma: a retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990;16:500-6.
8. Haak HR, Cornelisse CJ, Hermans J, Cobben L, Fleuren GJ. Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br J Cancer 1993;68:151-5.
9. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994;78:790-4.
10. McNicol AM, Nolan CE, Struthers AJ, Farquharson MA, Herman J, Haak HR. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol 1997;181:146-52.
11. Suzuki T, Sasano H, Nisikawa T, Rhame J, Wilkinson DS, Nagura H. Discerning malignancy in human adrenocortical neoplasms: utility of DNA flow cytometry and immunohistochemistry. Mod Pathol 1992;5:224-30.
12. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8.
13. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995;8(1):11-7.
14. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, et al. DNA topoisomerase 11α and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 1997;10:901-7.
15. Edgren M, Eriksson B, Wilander E, Westlin JE, Nilsson S, Oberg K. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EFR-r, Ki-67 and PCBA in 17 adrenocortical carcinomas. Anticancer Res 1997;17:1303-10.
16. Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 1998;11(12):1165-70.
17. Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2002;34:54-64.
18. Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DH, Ghossein RA. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002;160:175-83.
19. Hoos A, Urist M, Stojadinovic A, Mastorides S, Dudas ME, Leung DHY, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens. Am J Pathol 2001;158:1245-51.
20. Schulik RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annu Surg Oncol 1999;6:719-26.
21. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-5.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
23. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543-9.
24. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
25. Reincke M. Mutations in adrenocortical tumors. Horm Metab Res 1998;30:447-55.
26. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature (Lond) 1991;351:453-6.
27. Momand J, Zambetti GP, Olson DC, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
28. Zirbes TK, Baldus SE, Moenig SP, Nolden S, Kunze D, Shafizadeh ST, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-8.
29. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
30. Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/DIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 1997;75:1617-20.
31. Kip1, in human malignancies. Cancer Res 1995;55:2266-9.
32. Kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int J Cancer 2000;88:377-83.